Quantcast
Last updated on April 16, 2014 at 14:39 EDT

Latest Æterna Zentaris Stories

2012-06-14 02:24:37

QUÉBEC CITY, June 14, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Jose M. Garcia, MD, PhD, of the Baylor College of Medicine and the Michael E. DeBakey VA Medical Center in Houston, Texas, will be making an oral presentation on Phase 3 results for AEZS-130 as an oral diagnostic test for Adult Growth Hormone Deficiency (AGHD), at the 94(th )ENDO Annual Meeting and Expo which will be held June 23-26, 2012,...

2012-05-16 10:24:46

QUEBEC CITY, May 16, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)   (the "Company") announced today that it has received a notice from The NASDAQ Stock Market indicating that the Company's minimum bid price has fallen below $1.00 for 30 consecutive business days, and, therefore, was not in compliance with NASDAQ Marketplace Rule 5450(a)(1). The Company has been provided 180 calendar days, or until November 12, 2012,...

2012-05-09 02:26:14

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, May 9, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), today reported financial and operating results as at and for the first quarter ended March 31, 2012. Highlights AEZS-108 (LHRH-Targeted Cytotoxic Conjugate) -- Agreement signed with Ventana Medical Systems, Inc., a member of the Roche Group, to develop a companion diagnostic for...

2012-05-07 02:32:05

NEW YORK, May 7, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the Company and Aeterna Zentaris Inc. have executed a License Termination and Technology Transfer Agreement, whereby the KRX-0401 (perifosine) license agreement has been terminated and all license rights have reverted back to Aeterna Zentaris. In exchange for the transfer of the U.S. Investigational New Drug Application, development data, intellectual property and contracts to Aeterna...

2012-05-07 02:32:00

Aeterna Zentaris to continue ongoing Phase 3 trial in multiple myeloma QUEBEC CITY, May 7, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it and Keryx Biopharmaceuticals, Inc. ("Keryx") (NASDAQ: KERX) have agreed to terminate their license agreement with respect to perifosine, as a result of which Aeterna Zentaris has regained in full the North American rights to its Akt inhibitor anticancer compound, perifosine, in all...

2012-05-03 02:31:38

QUÉBEC CITY, May 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior VP and Chief Medical Officer, Paul Blake MD, will be presenting a corporate overview at the 11(th) Annual JMP Securities Research Conference on Monday, May 14, 2012, at 12 noon (Pacific), in the Terrace Room of the Ritz-Carlton Hotel in San Francisco. A live webcast of this presentation will be available on Aeterna Zentaris'...

2012-05-01 02:31:18

QUEBEC CITY, May 1, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its first quarter 2012 financial and operating results before market open on Wednesday, May 9, 2012. The Company will host a conference call to discuss these results later that same day at 8:30 a.m., Eastern Time. Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom" section, or by telephone using the following...

2012-04-02 02:27:43

QUÉBEC CITY, April 2, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the Phase 3 "X-PECT" (Xeloda® + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda®) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo. The trial involving 468 patients in 65...

2012-03-29 02:25:54

QUÉBEC CITY, March 29, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its President and CEO, Juergen Engel, PhD, will be presenting a corporate overview at the 11(th) Annual Needham Healthcare Conference on Wednesday, April 4, 2012, at 1:20 pm (Eastern), in the Henry Room of the New York Palace Hotel, in New York City. A live webcast of this slide presentation will be available on Aeterna Zentaris'...

2012-03-26 02:25:32

QUÉBEC CITY, March 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced poster presentations on two of its anticancer compounds, perifosine and AEZS-136, at the upcoming American Association for Cancer Research ("AACR") meeting to be held March 31 - April 4, 2012, at the McCormick Place in Chicago. Sunday, April 1, 2012 / 1pm- 5pm (Central) Abstract #871: "Dual inhibition of PI3K and Erk1/2 shows...